These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35635038)

  • 1. ApoB and Non-HDL Cholesterol Versus LDL Cholesterol for Ischemic Stroke Risk.
    Johannesen CDL; Mortensen MB; Langsted A; Nordestgaard BG
    Ann Neurol; 2022 Sep; 92(3):379-389. PubMed ID: 35635038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Lipoprotein Lipids, Apolipoproteins and Ischemic Stroke.
    Yuan S; Tang B; Zheng J; Larsson SC
    Ann Neurol; 2020 Dec; 88(6):1229-1236. PubMed ID: 32981134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.
    Robinson JG; Wang S; Jacobson TA
    Am J Cardiol; 2012 Nov; 110(10):1468-76. PubMed ID: 22906895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.
    Sathiyakumar V; Park J; Quispe R; Elshazly MB; Michos ED; Banach M; Toth PP; Whelton SP; Blumenthal RS; Jones SR; Martin SS
    Circulation; 2018 Jul; 138(3):244-254. PubMed ID: 29506984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
    Pischon T; Girman CJ; Sacks FM; Rifai N; Stampfer MJ; Rimm EB
    Circulation; 2005 Nov; 112(22):3375-83. PubMed ID: 16316964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.
    Johannesen CDL; Mortensen MB; Langsted A; Nordestgaard BG
    J Am Coll Cardiol; 2021 Mar; 77(11):1439-1450. PubMed ID: 33736827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordance between apolipoprotein B or non-HDL-cholesterol and LDL-cholesterol in middle-aged and elderly Chinese patients predicts arterial stiffness.
    Qu G; Zhang Z; Zhu H
    Lipids Health Dis; 2021 Jul; 20(1):80. PubMed ID: 34325713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE).
    O'Donnell MJ; McQueen M; Sniderman A; Pare G; Wang X; Hankey GJ; Rangarajan S; Chin SL; Rao-Melacini P; Ferguson J; Xavier D; Lisheng L; Zhang H; Pais P; Lopez-Jaramillo P; Damasceno A; Langhorne P; Rosengren A; Dans AL; Elsayed A; Avezum A; Mondo C; Judge C; Diener HC; Ryglewicz D; Czlonkowska A; Pogosova N; Weimar C; Iqbal R; Diaz R; Yusoff K; Yusufali A; Oguz A; Penaherrera E; Lanas F; Ogah OS; Ogunniyi A; Iversen HK; Malaga G; Rumboldt Z; Oveisgharan S; Al Hussain F; Nilanont Y; Yusuf S;
    J Stroke; 2022 May; 24(2):224-235. PubMed ID: 35677977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
    Ballantyne CM; Raichlen JS; Cain VA
    J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordance between LDL-C and apolipoprotein B is associated with large-artery-atherosclerosis ischemic stroke in patients ⩽70 years of age.
    Kriemler L; Rudin S; Gawinecka J; Gross F; Arnold M; Schweizer J; Westphal L; Inauen C; Pokorny T; Dittrich T; Toebak A; Arnold M; Christ-Crain M; von Eckardstein A; Rentsch K; Katan M; De Marchis GM
    Eur Stroke J; 2024 Jun; 9(2):494-500. PubMed ID: 38279527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.
    Fonseca L; Paredes S; Ramos H; Oliveira JC; Palma I
    Lipids Health Dis; 2020 Jun; 19(1):127. PubMed ID: 32505210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
    Walldius G; Jungner I; Aastveit AH; Holme I; Furberg CD; Sniderman AD
    Clin Chem Lab Med; 2004; 42(12):1355-63. PubMed ID: 15576296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?
    Langlois MR; Sniderman AD
    Curr Cardiol Rep; 2020 Jun; 22(8):67. PubMed ID: 32562186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-high-density lipoprotein cholesterol vs low-density lipoprotein cholesterol as a risk factor for ischemic stroke: a result from the Kailuan study.
    Wu J; Chen S; Liu L; Gao X; Zhou Y; Wang C; Zhang Q; Wang A; Hussain M; Sun B; Wu S; Zhao X
    Neurol Res; 2013 Jun; 35(5):505-11. PubMed ID: 23594748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid levels and the risk of ischemic stroke in women.
    Kurth T; Everett BM; Buring JE; Kase CS; Ridker PM; Gaziano JM
    Neurology; 2007 Feb; 68(8):556-62. PubMed ID: 17310025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.
    Mariosa D; Hammar N; Malmström H; Ingre C; Jungner I; Ye W; Fang F; Walldius G
    Ann Neurol; 2017 May; 81(5):718-728. PubMed ID: 28437840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.